Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 66 entries
Sorted by: Best Match Show Resources per page
Nausea and Vomiting.

Current treatment options in gastroenterology

Fraga XF, Malagelada JR.
PMID: 12095471
Curr Treat Options Gastroenterol. 2002 Aug;5(4):241-250. doi: 10.1007/s11938-002-0046-6.

Nausea and vomiting are rather stereotyped symptoms. The challenge is that nausea and vomiting have many different causes and, in some patients, management may be rather complex. The clue is to determine the causal factor early. It helps to...

Cite
Fraga XF, Malagelada JR. Nausea and Vomiting. Curr Treat Options Gastroenterol. 2002;5(4):241-250doi: 10.1007/s11938-002-0046-6.
Fraga, X. F., & Malagelada, J. R. (2002). Nausea and Vomiting. Current treatment options in gastroenterology, 5(4), 241-250. https://doi.org/10.1007/s11938-002-0046-6
Fraga, Xose Fernández, and Malagelada, Juan R.. "Nausea and Vomiting." Current treatment options in gastroenterology vol. 5,4 (2002): 241-250. doi: https://doi.org/10.1007/s11938-002-0046-6
Fraga XF, Malagelada JR. Nausea and Vomiting. Curr Treat Options Gastroenterol. 2002 Aug;5(4):241-250. doi: 10.1007/s11938-002-0046-6. PMID: 12095471.
Copy Download .nbib Format: NLM
Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Gutleben KJ, Eller J, Vöckler J, Rau M, Koeppe P, Kotwas J, Lode H.
PMID: 11864100
Clin Microbiol Infect. 1997 Apr;3(2):170-174. doi: 10.1111/j.1469-0691.1997.tb00593.x.

OBJECTIVE: To evaluate the pharmacokinetics of cefetamet pivoxil and possible interaction with N-acetylcysteine and cisapride in healthy volunteers. METHODS: In a double-blind, randomized three-way crossover study with 12 healthy male volunteers, serum and urine concentrations of cefetamet were determined...

Cite
Gutleben KJ, Eller J, Vöckler J, et al. Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. Clin Microbiol Infect. 1997;3(2):170-174doi: 10.1111/j.1469-0691.1997.tb00593.x.
Gutleben, K. J., Eller, J., Vöckler, J., Rau, M., Koeppe, P., Kotwas, J., & Lode, H. (1997). Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 3(2), 170-174. https://doi.org/10.1111/j.1469-0691.1997.tb00593.x
Gutleben, Klaus-Jürgen, et al. "Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine." Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 3,2 (1997): 170-174. doi: https://doi.org/10.1111/j.1469-0691.1997.tb00593.x
Gutleben KJ, Eller J, Vöckler J, Rau M, Koeppe P, Kotwas J, Lode H. Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. Clin Microbiol Infect. 1997 Apr;3(2):170-174. doi: 10.1111/j.1469-0691.1997.tb00593.x. PMID: 11864100.
Copy Download .nbib Format: NLM
Effectiveness and safety of a protocol for promotion of early intragastric feeding in critically ill children.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies

Briassoulis GC, Zavras NJ, Hatzis MD TD.
PMID: 12797869
Pediatr Crit Care Med. 2001 Apr;2(2):113-21. doi: 10.1097/00130478-200104000-00004.

OBJECTIVES: To investigate the feasibility, adequacy, and efficacy of early poststress intragastric feeding (EPIGF) in critically ill children. DESIGN: A prospective clinical study. SETTING: Pediatric intensive care unit in a tertiary care children's hospital. PATIENTS: Seventy-one consecutively enrolled critically...

Cite
Briassoulis GC, Zavras NJ, Hatzis MD TD. Effectiveness and safety of a protocol for promotion of early intragastric feeding in critically ill children. Pediatr Crit Care Med. 2001;2(2):113-21doi: 10.1097/00130478-200104000-00004.
Briassoulis, G. C., Zavras, N. J., & Hatzis MD, T. D. (2001). Effectiveness and safety of a protocol for promotion of early intragastric feeding in critically ill children. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2(2), 113-21. https://doi.org/10.1097/00130478-200104000-00004
Briassoulis, G C, et al. "Effectiveness and safety of a protocol for promotion of early intragastric feeding in critically ill children." Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies vol. 2,2 (2001): 113-21. doi: https://doi.org/10.1097/00130478-200104000-00004
Briassoulis GC, Zavras NJ, Hatzis MD TD. Effectiveness and safety of a protocol for promotion of early intragastric feeding in critically ill children. Pediatr Crit Care Med. 2001 Apr;2(2):113-21. doi: 10.1097/00130478-200104000-00004. PMID: 12797869.
Copy Download .nbib Format: NLM
Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry.

Rapid communications in mass spectrometry : RCM

Kantharaj E, Tuytelaars A, Proost PE, Ongel Z, Van Assouw HP, Gilissen RA.
PMID: 14648905
Rapid Commun Mass Spectrom. 2003;17(23):2661-8. doi: 10.1002/rcm.1228.

The use of in vitro drug metabolism data in the understanding of in vivo pharmacokinetic, safety and toxicity data has become a large area of scientific interest. This has stemmed from a trend in the pharmaceutical industry to use...

Cite
Kantharaj E, Tuytelaars A, Proost PE, et al. Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry. Rapid Commun Mass Spectrom. 2003;17(23):2661-8doi: 10.1002/rcm.1228.
Kantharaj, E., Tuytelaars, A., Proost, P. E., Ongel, Z., Van Assouw, H. P., & Gilissen, R. A. (2003). Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry. Rapid communications in mass spectrometry : RCM, 17(23), 2661-8. https://doi.org/10.1002/rcm.1228
Kantharaj, E, et al. "Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry." Rapid communications in mass spectrometry : RCM vol. 17,23 (2003): 2661-8. doi: https://doi.org/10.1002/rcm.1228
Kantharaj E, Tuytelaars A, Proost PE, Ongel Z, Van Assouw HP, Gilissen RA. Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry. Rapid Commun Mass Spectrom. 2003;17(23):2661-8. doi: 10.1002/rcm.1228. PMID: 14648905.
Copy Download .nbib Format: NLM
Treatment of Functional Dyspepsia.

Current treatment options in gastroenterology

Delgado-Aros S, Cremonini F, Talley NJ.
PMID: 15010026
Curr Treat Options Gastroenterol. 2004 Apr;7(2):121-131. doi: 10.1007/s11938-004-0033-1.

Functional dyspepsia is a common chronic condition. It can have a major impact on quality of life and remains a large burden on healthcare resources. Its underlying mechanisms are not fully understood and therapies are mainly empirical. In this...

Cite
Delgado-Aros S, Cremonini F, Talley NJ. Treatment of Functional Dyspepsia. Curr Treat Options Gastroenterol. 2004;7(2):121-131doi: 10.1007/s11938-004-0033-1.
Delgado-Aros, S., Cremonini, F., & Talley, N. J. (2004). Treatment of Functional Dyspepsia. Current treatment options in gastroenterology, 7(2), 121-131. https://doi.org/10.1007/s11938-004-0033-1
Delgado-Aros, Silvia, et al. "Treatment of Functional Dyspepsia." Current treatment options in gastroenterology vol. 7,2 (2004): 121-131. doi: https://doi.org/10.1007/s11938-004-0033-1
Delgado-Aros S, Cremonini F, Talley NJ. Treatment of Functional Dyspepsia. Curr Treat Options Gastroenterol. 2004 Apr;7(2):121-131. doi: 10.1007/s11938-004-0033-1. PMID: 15010026.
Copy Download .nbib Format: NLM
Tolerability of leukotriene modifiers in asthma: a review of clinical experience.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Reques FG, Rodriguez JL.
PMID: 18031150
BioDrugs. 1999 Jun;11(6):385-94. doi: 10.2165/00063030-199911060-00003.

The so called leukotriene antagonists or, more accurately, the leukotriene modifiers are a rather heterogeneous set of drugs that work by several mechanisms. Such mechanisms include: (i) 5-lipoxygenase enzyme inhibition (e.g. zileuton); (ii) 5-lipoxygenase-activating-protein inhibition (e.g. quiflapon, BAYx 1005);...

Cite
Reques FG, Rodriguez JL. Tolerability of leukotriene modifiers in asthma: a review of clinical experience. BioDrugs. 1999;11(6):385-94doi: 10.2165/00063030-199911060-00003.
Reques, F. G., & Rodriguez, J. L. (1999). Tolerability of leukotriene modifiers in asthma: a review of clinical experience. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 11(6), 385-94. https://doi.org/10.2165/00063030-199911060-00003
Reques, F G, and Rodriguez, J L. "Tolerability of leukotriene modifiers in asthma: a review of clinical experience." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 11,6 (1999): 385-94. doi: https://doi.org/10.2165/00063030-199911060-00003
Reques FG, Rodriguez JL. Tolerability of leukotriene modifiers in asthma: a review of clinical experience. BioDrugs. 1999 Jun;11(6):385-94. doi: 10.2165/00063030-199911060-00003. PMID: 18031150.
Copy Download .nbib Format: NLM
Tumor-grade hyperprolactinemia induced by multiple medications in the setting of renal failure.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Ziambaras K, Dagogo-Jack S.
PMID: 15251686
Endocr Pract. 1999 May-Jun;5(3):139-42. doi: 10.4158/EP.5.3.139.

OBJECTIVE: To describe a patient with galactorrhea and severe hyperprolactinemia in whom workup revealed a nontumoral mechanism.METHODS: We present the medical history of a woman with long-standing diabetes in whom bilateral galactorrhea and hyperprolactinemia developed. In addition, the details...

Cite
Ziambaras K, Dagogo-Jack S. Tumor-grade hyperprolactinemia induced by multiple medications in the setting of renal failure. Endocr Pract. 1999;5(3):139-42doi: 10.4158/EP.5.3.139.
Ziambaras, K., & Dagogo-Jack, S. (1999). Tumor-grade hyperprolactinemia induced by multiple medications in the setting of renal failure. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 5(3), 139-42. https://doi.org/10.4158/EP.5.3.139
Ziambaras, K, and Dagogo-Jack, S. "Tumor-grade hyperprolactinemia induced by multiple medications in the setting of renal failure." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 5,3 (1999): 139-42. doi: https://doi.org/10.4158/EP.5.3.139
Ziambaras K, Dagogo-Jack S. Tumor-grade hyperprolactinemia induced by multiple medications in the setting of renal failure. Endocr Pract. 1999 May-Jun;5(3):139-42. doi: 10.4158/EP.5.3.139. PMID: 15251686.
Copy Download .nbib Format: NLM
Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.

Clinical and experimental gastroenterology

Wong BS, Manabe N, Camilleri M.
PMID: 21694846
Clin Exp Gastroenterol. 2010;3:49-56. doi: 10.2147/ceg.s8091. Epub 2010 May 24.

Constipation affects up to a quarter of the population in developed countries and is associated with poor quality of life and significant economic burden. Many patients with chronic constipation are dissatisfied with current therapy due to lack of long-term...

Cite
Wong BS, Manabe N, Camilleri M. Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation. Clin Exp Gastroenterol. 2010;3:49-56doi: 10.2147/ceg.s8091.
Wong, B. S., Manabe, N., & Camilleri, M. (2010). Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation. Clinical and experimental gastroenterology, 349-56. https://doi.org/10.2147/ceg.s8091
Wong, Banny S, et al. "Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation." Clinical and experimental gastroenterology vol. 3 (2010): 49-56. doi: https://doi.org/10.2147/ceg.s8091
Wong BS, Manabe N, Camilleri M. Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation. Clin Exp Gastroenterol. 2010;3:49-56. doi: 10.2147/ceg.s8091. Epub 2010 May 24. PMID: 21694846; PMCID: PMC3108672.
Copy Download .nbib Format: NLM
Treatment of idiopathic persistent hiccups with positive pressure ventilation -a case report-.

The Korean journal of pain

Byun SH, Jeon YH.
PMID: 22514778
Korean J Pain. 2012 Apr;25(2):105-7. doi: 10.3344/kjp.2012.25.2.105. Epub 2012 Apr 04.

A 41-year-old male patient presented with idiopathic persistent hiccups. The hiccups did not respond to pharmacologic treatments including cisapride, omeprazole, and baclofen. Phrenic nerve block was also ineffective. However, the persistent hiccups were successfully treated with short-term positive pressure...

Cite
Byun SH, Jeon YH. Treatment of idiopathic persistent hiccups with positive pressure ventilation -a case report-. Korean J Pain. 2012;25(2):105-7doi: 10.3344/kjp.2012.25.2.105.
Byun, S. H., & Jeon, Y. H. (2012). Treatment of idiopathic persistent hiccups with positive pressure ventilation -a case report-. The Korean journal of pain, 25(2), 105-7. https://doi.org/10.3344/kjp.2012.25.2.105
Byun, Sung Hye, and Jeon, Young Hoon. "Treatment of idiopathic persistent hiccups with positive pressure ventilation -a case report-." The Korean journal of pain vol. 25,2 (2012): 105-7. doi: https://doi.org/10.3344/kjp.2012.25.2.105
Byun SH, Jeon YH. Treatment of idiopathic persistent hiccups with positive pressure ventilation -a case report-. Korean J Pain. 2012 Apr;25(2):105-7. doi: 10.3344/kjp.2012.25.2.105. Epub 2012 Apr 04. PMID: 22514778; PMCID: PMC3324734.
Copy Download .nbib Format: NLM
Methemoglobinemia associated with metoclopramide therapy in a neonate.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Palmer KG, James LP.
PMID: 23118691
J Pediatr Pharmacol Ther. 2004 Jan;9(1):49-54. doi: 10.5863/1551-6776-9.1.49.

With the removal of cisapride from the U.S. market, practitioners have increasingly used other medications, such as metoclopramide, to treat gastroesophageal reflux in pediatric patients. We describe the case of a neonate who developed methemoglobinemia after receiving metoclopramide at...

Cite
Palmer KG, James LP. Methemoglobinemia associated with metoclopramide therapy in a neonate. J Pediatr Pharmacol Ther. 2004;9(1):49-54doi: 10.5863/1551-6776-9.1.49.
Palmer, K. G., & James, L. P. (2004). Methemoglobinemia associated with metoclopramide therapy in a neonate. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 9(1), 49-54. https://doi.org/10.5863/1551-6776-9.1.49
Palmer, Kristine G, and James, Laura P. "Methemoglobinemia associated with metoclopramide therapy in a neonate." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 9,1 (2004): 49-54. doi: https://doi.org/10.5863/1551-6776-9.1.49
Palmer KG, James LP. Methemoglobinemia associated with metoclopramide therapy in a neonate. J Pediatr Pharmacol Ther. 2004 Jan;9(1):49-54. doi: 10.5863/1551-6776-9.1.49. PMID: 23118691; PMCID: PMC3469149.
Copy Download .nbib Format: NLM
Design and evaluation of hydrophobic coated buoyant core as floating drug delivery system for sustained release of cisapride.

Journal of basic and clinical pharmacy

Jacob S, Nair AB, Patil PN.
PMID: 24825997
J Basic Clin Pharm. 2010 Dec;2(1):11-9. Epub 2011 Feb 15.

An inert hydrophobic buoyant coated-core was developed as floating drug delivery system (FDDS) for sustained release of cisapride using direct compression technology. Core contained low density, porous ethyl cellulose, which was coated with an impermeable, insoluble hydrophobic coating polymer...

Cite
Jacob S, Nair AB, Patil PN. Design and evaluation of hydrophobic coated buoyant core as floating drug delivery system for sustained release of cisapride. J Basic Clin Pharm. 2011;2(1):11-9
Jacob, S., Nair, A. B., & Patil, P. N. (2010). Design and evaluation of hydrophobic coated buoyant core as floating drug delivery system for sustained release of cisapride. Journal of basic and clinical pharmacy, 2(1), 11-9.
Jacob, Shery, et al. "Design and evaluation of hydrophobic coated buoyant core as floating drug delivery system for sustained release of cisapride." Journal of basic and clinical pharmacy vol. 2,1 (2010): 11-9.
Jacob S, Nair AB, Patil PN. Design and evaluation of hydrophobic coated buoyant core as floating drug delivery system for sustained release of cisapride. J Basic Clin Pharm. 2010 Dec;2(1):11-9. Epub 2011 Feb 15. PMID: 24825997; PMCID: PMC3979204.
Copy Download .nbib Format: NLM
Electroacupuncture at ST25 Inhibits Cisapride-Induced Gastric Motility in an Intensity-Dependent Manner.

Evidence-based complementary and alternative medicine : eCAM

Pang T, Lu C, Wang K, Liang C, Yu Z, Zhu B, Xu B.
PMID: 26997963
Evid Based Complement Alternat Med. 2016;2016:3457025. doi: 10.1155/2016/3457025. Epub 2016 Feb 22.

Background. Previous studies have demonstrated the efficacy of frequency-specific EAS. However, evaluation of intensity-response effects is challenging and has yet to be addressed. Aims. Using cisapride to promote gastric emptying, we measured the intensity-response relationship of EA at ST25...

Cite
Pang T, Lu C, Wang K, et al. Electroacupuncture at ST25 Inhibits Cisapride-Induced Gastric Motility in an Intensity-Dependent Manner. Evid Based Complement Alternat Med. 2016;2016:3457025doi: 10.1155/2016/3457025.
Pang, T., Lu, C., Wang, K., Liang, C., Yu, Z., Zhu, B., & Xu, B. (2016). Electroacupuncture at ST25 Inhibits Cisapride-Induced Gastric Motility in an Intensity-Dependent Manner. Evidence-based complementary and alternative medicine : eCAM, 20163457025. https://doi.org/10.1155/2016/3457025
Pang, Tingting, et al. "Electroacupuncture at ST25 Inhibits Cisapride-Induced Gastric Motility in an Intensity-Dependent Manner." Evidence-based complementary and alternative medicine : eCAM vol. 2016 (2016): 3457025. doi: https://doi.org/10.1155/2016/3457025
Pang T, Lu C, Wang K, Liang C, Yu Z, Zhu B, Xu B. Electroacupuncture at ST25 Inhibits Cisapride-Induced Gastric Motility in an Intensity-Dependent Manner. Evid Based Complement Alternat Med. 2016;2016:3457025. doi: 10.1155/2016/3457025. Epub 2016 Feb 22. PMID: 26997963; PMCID: PMC4779844.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 66 entries